Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) has completed patient enrollment in its Phase 2 trial of relacorilant combined with nab-paclitaxel for treating metastatic, platinum-resistant ovarian cancer. A total of 177 patients were enrolled across 28 sites in North America and Europe. The primary endpoint focuses on progression-free survival, alongside secondary measures like objective response rates. Following promising Phase 1/2 results, data from this trial are expected in the first half of the next year, positioning Corcept for potential advancements in its clinical portfolio.
Corcept Therapeutics (NASDAQ: CORT) has commenced the RELIANT trial, an open-label, Phase 3 study evaluating relacorilant in combination with nab-paclitaxel for treating metastatic pancreatic cancer. The trial aims to enroll 80 patients, with the primary endpoint being objective response rate. Interim data will be analyzed after the first 40 patients are enrolled. This follows encouraging results from a Phase 1/2 study presented at ASCO last year, indicating potential for accelerated approval if results are positive.
Corcept Therapeutics (NASDAQ: CORT) will present new genomic data on adrenocortical carcinoma at the 2020 AACR Annual Meeting, starting June 22. The data, which addresses excessive cortisol, is critical for their Phase 1b trial of relacorilant with pembrolizumab in patients with advanced cancer. This research aims to enhance immunotherapy's efficacy by mitigating cortisol's negative effects. The poster presentation is set for a virtual format and will be available online following the meeting.
Corcept Therapeutics reported Q1 2020 financial results with revenue of $93.2 million, up 44% year-over-year. GAAP net income rose to $30.1 million, with diluted EPS of $0.25. Non-GAAP diluted EPS was $0.34, compared to $0.20 in Q1 2019. Cash and investments increased to $349.0 million. The company maintained its 2020 revenue guidance of $355-375 million. However, COVID-19 has impacted clinical trial enrollments and timelines, but the firm anticipates ongoing developments and results from ongoing trials this year.
Summary not available.